Evaluation of SubcutaneousRush Immunotherapy Effectiveness in Perennial Allergic Rhinitis after a Year from Treatment

Document Type: Original

Authors

1 Department of Pediatric , Faculty of Medicine, Zahedan University of Medical Sciences Zahedan, Iran.

2 Allergy Research Center, Mashhad University of Medical Sciences, Mashhad, Iran.

3 Department of Pediatric , Shahid Rahimi Hospital, Lorestan University of Medical Sciences, Khorram Abad, Iran.

4 Department of Biomedical Informatics, Facultyof Medicine, Mashhad University of Medical Sciences, Mashhad, Iran.

Abstract

Introduction:
Allergen immunotherapy is an effective treatment for allergic rhinitis. Conventional immunotherapy takesat least 5 to 6 months to reach the maintenance dosage; nonetheless, rush immunotherapy accelerates to reach the maintenance dose several months earlier. However, the safety and efficacy of this treatment has not been widely investigated. The objective of the present study was to determine the efficacy of subcutaneous rush immunotherapy in the patients with perennial allergic rhinitis after a year from treatment.
 
Materials and Methods:
This study was carried out on a total of 15 patients with allergic rhinitis who received rush immunotherapy and were evaluated for the quality of life and clinical symptoms improvement with Sino-Nasal Outcome Test Questionnaire (SNOT-22) and Mini Rhinoconjunctivitis Quality of Life Questionnaire (RQLQ) before and after a year from treatment. Moreover, specific weed mix Immunoglobulin E (IgE) was measured before and after a year from treatment. Statistical analysis was performed using SPSS software (version 16) (P0.001).
 
Conclusion:
Rush immunotherapy is an effective treatment in the patients with allergic rhinitis. It seems to be an alternative treatment in cases that need more rapid treatment. However, it is recommended to carry out other studiesonthe control group.

Keywords


1. Di Lorenzo G, Pacor ML, Amodio E, Leto-Barone MS, La Piana S, D’Alcamo A, et al. Differences and similarities between allergic and nonallergic rhinitis in a large sample of adult patients with rhinitis symptoms. International archives of allergy and immunology. 2011;155(3):263-70 2. Zhang L, Han D, Huang D, Wu Y, Dong Z, Xu G, et al. Prevalence of self-reported allergic rhinitis in eleven major cities in china. International archives of allergy and immunology. 2009;149(1):47-57. 3. Mahboubi Oskouei Y, Farid Hosseini R, Ahanchian H, Jarahi L, Ariaee N, Jabbari Azad F. Report of Common Aeroallergens among Allergic Patients in Northeastern Iran. Iranian journal of Otorhinolaryngology. 2017;29(91):89. 4. Dursun A, Sin B, Oner F, Misirligil Z. The safety of allergen immunotherapy (IT) in Turkey. Journal of investigational allergology and clinical immunology. 2006;16(2):123. 5. Brüggenjürgen B, Reinhold T, Brehler R, Laake E, Wiese G, Machate U, et al. Cost-effectiveness of specific subcutaneous immunotherapy in patients with allergic rhinitis and allergic asthma. Annals of Allergy, Asthma&Immunology. 2008;101(3): 316-24. 6. Walker S, Varney V, Gaga M, Jacobson M, Durham S. Grass pollen immunotherapy: efficacy and safety during a 4‐year follow‐up study. Allergy. 1995;50(5):405-13. 7. Cox L, Calderon MA. Subcutaneous specific immunotherapy for seasonal allergic rhinitis: a review of treatment practicesin the US and Europe. Current medical research and opinion. 2010;26(12):2723-33. 8. Wambre E, DeLong JH, James EA, LaFond RE, Robinson D, Kwok WW. Differentiation stage determines pathologic and protective allergen-specific CD4+ T-cell outcomes during specific immunotherapy. Journal of Allergy and Clinical Immunology. 2012;129(2):544-51. e7. 9. Moote W, Kim H. Allergen-specific immunotherapy. Allergy, Asthma & Clinical Immunology. 2011;7(1):S5. 10. Sheikh A, Hurwitz B, Shehata Y. House dust mite avoidance measures for perennial allergic rhinitis. Cochrane Database Syst Rev. 2007;1. 11. SchwankeT, Carragee E, Bremberg M, Reisacher WR. Quality-of-life outcomes in patients who underwent subcutaneous immunotherapy and sublingual immunotherapy in a real-world clinical setting. American journal of rhinology & allergy. 2017;31(5):310-6. 12. Roger A, Campillo EA, Torres M, Millan C, Jáuregui I, Mohedano E, et al. Reduced work/academic performance and quality of life in patients with allergic rhinitis and impact of allergen immunotherapy. Allergy, Asthma & Clinical Immunology. 2016;12(1):40. 13. Corsico AG, De Amici M, Ronzoni V, Giunta V, Mennitti MC, Viscardi A, et al. Allergen-specific immunoglobulin E and allergic rhinitis severity. Allergy & Rhinology. 2017;8(1):e1. 14. Lee J-H, Kim S-H, Lee WY, Yong SJ, Shin KC, Lee MK, et al. Immunotherapy -2079. Comparisonof house dust mite specific IgE and IgG4 between patients receiving rush immunotheraopy and conventional immunotherapy. World Allergy Organization Journal. 2013;6(1):P161-P.